Braems, Elke http://orcid.org/0000-0001-6158-9208
Bercier, Valérie
Van Schoor, Evelien
Heeren, Kara
Beckers, Jimmy
Fumagalli, Laura
Dedeene, Lieselot
Moisse, Matthieu
Geudens, Ilse
Hersmus, Nicole
Mehta, Arpan R.
Selvaraj, Bhuvaneish T.
Chandran, Siddharthan
Ho, Ritchie
Thal, Dietmar R.
Van Damme, Philip
Swinnen, Bart
Van Den Bosch, Ludo
Funding for this research was provided by:
Vlaams Instituut voor Biotechnologie
KU Leuven
Fonds Wetenschappelijk Onderzoek (G0C1620N, 1145621N, 1S46219N, 11A2321N, 12Y9120N, G0F8516N)
ALS Association
Fondation Thierry Latran
Association Belge contre les Maladies Neuro-Musculaires
Muscular Dystrophy Association
ALS Liga
Target ALS
E. von Behring Chair for Neuromuscular Disorders
Anne Rowling-DRI fellowship
UK Dementia Research Institute
Lady Edith Wolfson
Medical Research Council
Motor Neurone Disease Association
Anne Rowling
Article History
Received: 6 May 2022
Revised: 24 June 2022
Accepted: 11 July 2022
First Online: 27 July 2022
Declarations
:
: L.V.D.B. received speaker honorary from UCB (Brussels, Belgium) and Grünenthal (Aachen, Germany), is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). D.R.T. received speaker honorary or travel reimbursement from Novartis Pharma AG (Basel, Switzerland), UCB (Brussels, Belgium) and GE Healthcare (Amersham, UK) and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK) and Janssen Pharmaceutical Companies (Beerse, Belgium). D.R.T. serves in the editorial board of Acta Neuropathologica, but was not involved in the handling of this manuscript at any stage. P.V.D. participated in advisory board meetings of Biogen (Cambridge, MA, US), Cytokinetics (San Francisco, CA, US), Ferrer (Barcelona, Spain), UCB (Brussels, Belgium), Argenx (Ghent, Belgium), Muna Therapeutics (Copenhagen, Denmark), Alector (San Francisco, CA, US), Augustine Therapeutics (Leuven, Belgium), Alexion Therapeutics (Boston, MA, US) and QurAlis (Cambridge, MA, US).
: All zebrafish experiments performed were approved by the Ethical Committee for Animal Experimentation of the KU Leuven (P112/2021). Primary human fibroblasts were obtained from skin biopsies of ALS patients and controls with the approval of the Ethical Committee of the University Hospitals Leuven (S50354). The Ethical Committee of the University Hospitals Leuven has approved all experiments using human autopsy material (S65097, S59292, S60803).